Goldman Sachs Initiates United Therapeutics with Sell Rating and $321 Target

Key Facts

1Goldman Sachs initiated coverage on United Therapeutics with a 'Sell' rating and a $321 price target, 34.4% below its current price.

2CEO Martine Rothblatt sold 9,500 shares of the company for a total of approximately $4.70 million.

In a move reflecting a cautious outlook on the biotechnology sector's growth prospects, Goldman Sachs has initiated coverage on United Therapeutics (UTHR) with a 'Sell' rating. Analyst Andrea Newkirk set a price target of $321.00, representing a significant 34.4% downside from current market levels. The bearish initiation is driven by technical weakness, with the stock trading below key moving averages, alongside notable reductions in institutional stakes.

This pessimistic view coincides with significant insider activity, as CEO Martine Rothblatt sold 9,500 shares valued at approximately $4.70 million. According to market data, this rating comes as Goldman Sachs (GS) closed at $936.36 on September 23, 2026, while industry peers JPMorgan (JPM) and Morgan Stanley (MS) stood at $337.53 and $198.39 respectively as of the same close.

United Therapeutics closed at $198.39 on September 23, 2026, remaining well below its 50-day moving average of $514.05. Investors are now watching for potential support levels as institutional selling persists. While the upcoming economic calendar features several Federal Reserve speeches from officials like Bowman and Schmid, there are no immediate sector-specific catalysts scheduled for the remainder of the week.